Обратная связьPICO question 1: TB screening approaches in children 10 years of age
Which screening tools should be used to screen systematically for TB disease in children aged below 10 years accessing health care?
a. In children aged below 10 years accessing health care in high TB prevalence settings, should systematic screening for PTB using chest radiography (CXR) be used against a composite reference standard?
b. In children aged below 10 years accessing health care in high TB prevalence settings, should systematic screening for pulmonary TB using symptom screen be used against a composite reference standard?
PICO question 2: TB diagnostic approaches in children
a. In children aged below 10 years with presumptive pulmonary TB attending health care facilities, should integrated treatment-decision algorithms be used to diagnose pulmonary TB, compared to a microbiological or composite reference standard?
b. In children aged below 10 years with signs and symptoms of pulmonary TB, seeking care at health care facilities, should Xpert Ultra in gastric aspirate or stool be used to diagnose pulmonary TB and rifampicin resistance, as compared with a microbiological/composite reference standard?
i. What is the diagnostic accuracy of Xpert Ultra in gastric aspirate and stool for pulmonary TB in children aged below 10 years, as compared with a microbiological and composite reference standard?
ii. What is the diagnostic accuracy of Xpert Ultra in gastric aspirate and stool for rifampicin resistance in children aged below 10 years, as compared with a microbiological and composite reference standard?
PICO question 3: Treatment shortening in children and adolescents with non-severe drug-susceptible TB
In children and adolescents with non-severe TB, should a 4-month intervention regimen versus the standard 6-month regimen conforming to WHO guidelines be used?
PICO question 4: Treatment of rifampicin-resistant/multidrug resistant TB (MDR/RR-TB)
a. In MDR/RR-TB patients aged below 6 years, should an all-oral treatment regimen containing bedaquiline versus other regimens conforming to WHO guidelines without bedaquiline be used?
b. In MDR/RR-TB patients aged below 3 years, should an all-oral treatment regimen containing delamanid versus other regimens conforming to WHO guidelines without delamanid be used?
PICO question 5: Treatment of paediatric TB meningitis
In children and adolescents with presumed or bacteriologically confirmed drug-susceptible TB meningitis, should a 6-month intensive regimen, compared to the 12-month regimen that conforms to current WHO guidelines be used?
PICO question 6: Models of care for TB case detection and TB prevention settings with a prevalence of TB in the general population of 100 per 100 000 or more:
a. In children and adolescents with signs and symptoms of TB, should decentralization of child and adolescent TB services versus centralized child and adolescent TB services (at referral or tertiary hospital level) be used?
b. In children and adolescents exposed to TB, should decentralization of child and adolescent TB prevention and care services versus centralized prevention and care services (at referral or tertiary hospital level) be used to increase coverage of TPT in eligible children and adolescents?
c. In children and adolescents with signs and symptoms of TB, should family-centred, integrated services versus standard, non-family-centred, non-integrated services be used?
d. In children and adolescents exposed to TB, should family-centred, integrated services versus standard, non-family-centred, non-integrated services be used to increase coverage of TPT in eligible children and adolescents?